PartnershipSolid Biosciences announced a nonexclusive worldwide licensing and collaboration agreement with Kinea Bio, receiving an upfront payment and eligibility for additional development and sales milestones.
Regulatory InteractionInteractions with regulators regarding SGT-003 are seen as a near-term catalyst for the stock, amid the recent volatility in FDA leadership and regulatory environment.
Safety ProfileSGT-003 continues to be well-tolerated with no treatment-emergent serious adverse events, indicating a strong safety profile.